Reply to the Editorial†
Corresponding Author
Weigong Zhou MD, PhD
Immunization Safety Branch, Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA, USA
Immunization Safety Branch, Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, 1600 Clifton Road, MS E-61, Atlanta, GA 30333, USA.Search for more papers by this authorVitali Pool MD
Immunization Safety Branch, Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA, USA
Search for more papers by this authorFrank DeStefano MD, MPH
Immunization Safety Branch, Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA, USA
Search for more papers by this authorJohn K. Iskander MD
Immunization Safety Branch, Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA, USA
Search for more papers by this authorPenina Haber MPH
Immunization Safety Branch, Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA, USA
Search for more papers by this authorRobert T. Chen MD, MA
Immunization Safety Branch, Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA, USA
Search for more papers by this authorCorresponding Author
Weigong Zhou MD, PhD
Immunization Safety Branch, Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA, USA
Immunization Safety Branch, Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, 1600 Clifton Road, MS E-61, Atlanta, GA 30333, USA.Search for more papers by this authorVitali Pool MD
Immunization Safety Branch, Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA, USA
Search for more papers by this authorFrank DeStefano MD, MPH
Immunization Safety Branch, Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA, USA
Search for more papers by this authorJohn K. Iskander MD
Immunization Safety Branch, Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA, USA
Search for more papers by this authorPenina Haber MPH
Immunization Safety Branch, Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA, USA
Search for more papers by this authorRobert T. Chen MD, MA
Immunization Safety Branch, Epidemiology and Surveillance Division, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA, USA
Search for more papers by this authorThis article is a U.S. Government work and is in the public domain in the U.S.A.
REFERENCES
- 1 Zhou W, Pool V, DeStefano F, Iskander J, Haber P, Chen RT. A potential signal of Bell's palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS)—United States, 1991–2001. Pharmacoepidemiol Drug Safe 2004; 13: 505–510.
- 2 Evans S. Statistical methods in signal detection. In Pharmacovigilance, RD Mann, EB Andrews (eds). John Wiley & Sons, Ltd.: Chichester, UK, 2002; 273–279.
10.1002/0470853093.ch20 Google Scholar
- 3 Evans SJW, Waller PC, Davis S. Use of proportional reporting ratio (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Safe 2001; 10: 1–4.
- 4 Zhou W, Pool V, Iskander JK, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)—United States, 1991–2001. MMWR 2003; 52(SS-1): 1–24.
- 5 Rosenthal S, Chen RT. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Public Health 1995; 85: 1706–1709.
- 6 Moore N, Hall G, Sturkenboom M, Mann R, Lagnaoui R, Begaud B. Biases affecting the proportional reporting ratio (PRR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Safe 2003; 12: 271–281.
- 7 Chapter 47: disease of the cranial nerves. In Principles of Neurology ( 7th edn), M Victor, AH Ropper (eds). McGraw-Hill Companies, Inc.: New York, New York, 2001; 1446–1463.
- 8 Chen RT. Vaccine risks: real, perceived and unknown. Vaccine 1999; 17(Suppl. 3): S41–S46.
- 9 Chen RT, DeStefano F, Davis RL, et al. The vaccine safety datalink: immunization research in health maintenance organizations in the USA. Bull World Health Organ 2000; 78(2): 186–194.
Citing Literature
